Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Gene Activator Protein May Be Key to Controlling Schistosomiasis

By LabMedica International staff writers
Posted on 16 Jan 2012
Parasitologists have identified a gene activator protein in Schistosoma mansoni that spurs development of the parasite after infection of its human host and is an attractive target for a new generation of drugs to control this disease.

Schistosome parasites infect more than 200 million people worldwide and cause human schistosomiasis. More...
Free-swimming schistosome larvae are highly mobile, and invade and penetrate the host's skin to perpetuate their lifecycle in their human host, growing from 90-215 µm in length as a schistosomulum to a 7-20 mm long adult worm. Few molecular pathways have been identified in schistosome worms that are important for parasite early development.

In the current study, investigators at Case Western Reserve University (Cleveland, OH, USA) focused on the gene activator protein myocyte enhancer factor 2 protein (Mef2). This protein a major regulator of muscle and nerve development in mammals and insects and is highly conserved from bread yeast to vertebrates.

They reported in the January 3, 2012, online edition of the journal PLoS Neglected Tropical Diseases that quantitative PCR demonstrated that Mef2 was expressed during several stages of schistosome development, and that it could bind to conserved Mef2 DNA consensus binding sequences. SmMef2 was shown to be a transactivator that could induce transcription of four separate heterologous reporter genes by yeast one-hybrid analysis.

The intent is to seek out drugs to target SMfe2. Although Mef2 is present in humans, the portion of SMef2 that switches on gene activity is so different from human Mef2 that it should be possible to target that part, and not affect the host.

“This is really a disease of poor people," said senior author Dr. Emmitt Jolly, professor of biology at Case Western Reserve University. “The strategy to combat the disease cannot be expensive.”

Related Links:

Case Western Reserve University



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.